Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2022-11-14 00:00:00 ET · period of report 2022-11-10 · accession 0001104659-22-117847 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-14 | 2022-11-10 | ROIV | Oren Dan | 10% | P - Purchase | $5.00 | +4.00M | 102.85M | +4% | +$20.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-11-10 | P | A | 4,000,000 | $5.00 | 102,849,443 | D | — | — | (F1) Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 4,684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity. (F2) The common shares were purchased by Dexcel in a registered public offering on November 10, 2022. |